US EditionPublished • loading... • Updated
General Proximity and Daiichi Sankyo Collaborate on Oncology
General Proximity will use its OmniTAC platform to identify novel effector-target pairs for first-in-class oncology therapeutics in collaboration with Daiichi Sankyo.
- On Nov. 12, 2025, General Proximity announced a strategic multi-target collaboration with Daiichi Sankyo through its Boston research institute to apply the OmniTAC platform to oncology programs and discover novel effector–target pairs.
- The scientific rationale centers on induced proximity approaches, as induced proximity medicines enable precise modification of disease‑driving proteins to target undruggable targets.
- The OmniTAC approach uses small molecules to bring two proteins into close proximity and induce therapeutic effects, and General Proximity is advancing multiple preclinical programs generated by the OmniTAC platform.
- In parallel, General Proximity will scale OmniTAC to other disease areas while advancing programs in cardiometabolic disease, neurodegeneration and longevity, reflecting a broad pipeline ambition.
- By enabling unbiased effector discovery, OmniTAC could unlock new therapeutic strategies by identifying effector proteins that modulate disease targets, positioning it as a differentiated drug discovery platform.
Insights by Ground AI
20 Articles
20 Articles
Montana Standard+18 Reposted by 18 other sources
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets.
Coverage Details
Total News Sources20
Leaning Left3Leaning Right0Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 30%
C 70%
Factuality
To view factuality data please Upgrade to Premium
